FDA nod to first-ever treatment for fatal pediatric Menkes disease

FDA accepts Sentynl Therapeutics CUTX-101 NDA resubmission

If approved, CUTX-101 will be the first and only FDA approved treatment available for Menkes disease

FDA issues CRL for Sentynl’s copper histidinate for treatment of Menkes disease

IPA welcomes Dr. Sharvil Patel as President and Glenn Saldanha as Vice President

ZyVet launches first generic treatment for canine urinary incontinence

Jagsonpal Pharmaceuticals appoints Amrut Medhekar as Chief Operating Officer

MedTech Expo 2025: ICMR licenses nine technologies to 17 industry partners

These licenses are given in areas of infectious disease diagnostics, immunodiagnostics, and vaccine development

Zynext Ventures invests in Feldan Therapeutics to drive innovation in intracellular drug delivery

Feldan's proprietary Shuttle peptide technology enables the efficient and targeted delivery of biomolecules into cells, unlocking new therapeutic possibilities

Zyuds Lifesciences receives USFDA approval for DMD treatment drug

Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older

Zynext Ventures invests in Illexcor Therapeutics to advance novel oral therapy for sickle cell disease

Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD